Former J&J and Novartis executive, Dr. Kathy Kordy, M.D. joins Cellbricks as Chief Medical Officer

April 28, 2025 – Berlin, Germany

Cellbricks is proud to announce the appointment of Dr. Kattayoun (Kathy) Kordy, M.D., as its new Chief Medical Officer.

Dr. Kordy’s arrival marks a pivotal milestone in the company’s journey to bring its groundbreaking regenerative bioprinting technology from the lab to the clinic.

With a proven track record in innovative drug development at global pharmaceutical leaders Novartis and Johnson & Johnson, Dr. Kordy brings deep clinical insight and strategic vision to Cellbricks. Her leadership will be instrumental as the company enters its next phase of growth—advancing bioprinted therapies with the potential to transform patient care.

“We are thrilled to welcome Dr. Kordy to the Cellbricks team,” said Alexander Leutner, Co-CEO of Cellbricks. “Her expertise and passion for innovation perfectly align with our mission to reshape the future of medicine through regenerative bioprinting.”